The main risk factors for post-LT MASLD identified in previous studies are diabetes, hypertension, hyperlipidemia, obesity/weight gain, genetic polymorphism PNPLA3, graft steatosis, LT indication (i.e., MASH, HCV, alcoholic liver disease) and immunosuppression.30 This evidence concerns the gene PNPLA3 and metabolic dysfunction-associated steatohepatitis.